This article was originally published in The Gray Sheet
Firm receives copy of second civil qui tam complaint Sept. 2 on "allegations under the False Claims Act" similar to charges a September 2003 whistleblower brought against its Sofamor Danek spinal division, according to Medtronic's recent 110-Q filing. The Department of Justice is investigating "certain payments and other services provided to physicians by Medtronic" that may have been "improper inducements under the federal anti-kickback statute." The case is under seal at Memphis federal court. In its quarterly report filed with SEC Aug. 13, BD revealed it has been cited by a qui tam complaint, also on the False Claims Act (2"The Gray Sheet" Aug. 30, 2004, p. 22)...
You may also be interested in...
Business considerations are as important as legal requirements for effective compliance programs, TAP Pharmaceutical Products VP and Ethics & Compliance Officer Stephan Vincze said Sept. 14 at a Food & Drug Law Institute meeting in Washington, D.C
BD maintains it is not the target of a U.S. Department of Justice criminal investigation of Novation, despite being subpoenaed to provide evidence in the case against the group purchasing organization
Siemens Healthineers' product mix of diagnostics and imaging products meant it was in the middle of a very dynamic situation when COVID-19 struck.